Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

ImmuPharma LSE:IMM Stock Surges 7.07%: Could New Pharma Partnerships Unlock Fresh Value?

ImmuPharma Plc — LSE:IMM gained7.07% on 14 August 2026, bringing renewed attention to the UK-listed specialist drug-development company.

Ankur Sharma | 17 August 2026

Could Genflow Biosciences PLC — LSE:GENF Be Emerging as a UK Longevity Biotech Stock to Watch After a 9.74% Surge?

Genflow Biosciences PLC — LSE:GENF has attracted renewed investor attention after gaining9.74% on 14 August 2026.

Ankur Sharma | 17 August 2026

Coiled Therapeutics LSE:COIL Stock Surges 5.56%: Could AO-252 Data Become the Next Major Catalyst?

Coiled Therapeutics Plc — LSE:COIL gained5.56% on 14 August 2026, bringing renewed attention to the newly restructured clinical-stage biotechnology company.

Ankur Sharma | 17 August 2026

Verici Dx LSE:VRCI Stock Falls 16.00%: Why Is the Kidney-Transplant Diagnostics Specialist Under Pressure on 14 August 2026?

Verici Dx PLC LSE:VRCI has come sharply into focus after its shares fell16.00% on 14 August 2026.

Ankur Sharma | 14 August 2026

Futura Medical Share Price Down 15.91%: Can Eroxon Intense and WSD4000 Rebuild Investor Confidence?

Futura Medical PLC LSE:FUM has come sharply into focus after its shares fell15.91% on 14 August 2026.

Ankur Sharma | 14 August 2026

Why Is Proteome Sciences LSE:PRM Up 8.89% as Clinical Proteomics Demand Accelerates?

Proteome Sciences LSE:PRM gained8.89% on 14 August 2026, bringing renewed attention to a specialist UK healthcare company operating in the rapidly evolving field of proteomics.

Ankur Sharma | 14 August 2026

HemoGenyx Pharmaceuticals Stock Builds Bullish Pressure as Clinical and Commercial Momentum Strengthens

HemoGenyx Pharmaceuticals develops treatments for blood cancers, autoimmune disorders and other serious diseases. Investor sentiment has improved as HG-CT-1 advances through clinical development and the company establishesManufacturingand commercial infrastructure. The stock’s rise also reflects renewed interest in differentiated oncology platforms, particularly therapies addressing diseases …

Ankur Sharma | 14 August 2026

Hemogenyx Pharmaceuticals Share Price Builds Bullish Pressure as CAR-T Commercialisation Pathway Strengthens Investor Optimism

Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for blood cancers, bone-marrow disorders, autoimmune conditions and severe viral diseases. Investor interest has recently improved following progress in its lead HG-CT-1 programme and the conversion of an earlier non-binding arrangement with Cellin Technologies into …

Ankur Sharma | 14 August 2026

Arecor Therapeutics Share Price Rises as Sentiment Toward Its Formulation-Technology Pipeline Improves

Arecor Therapeutics Plc is a biopharmaceutical company developing next-generation formulations of established therapeutic proteins, including ultra-rapid-acting insulin products, using its proprietary formulation technology. The shares advanced in the latest session, a move consistent with renewed investor interest in specialist biopharmaceutical formulation companies.

Ankur Sharma | 14 August 2026

Oxford Nanopore Technologies Shares Cool After Recent Momentum

Oxford Nanopore Technologies PLC (LSE:ONT) shares fell to 124.90p, down 1.20p, or 0.95%, according to the market data provided, easing back after a period of recent momentum for the genomics technology company.

Divya Sood | 14 August 2026
Support

Hi! How can we help you today?

Loading…